Abelacimab Effective Blood Clot Treatment, Study Suggests
Published:21 Jul.2021 Source:McMaster University
A potentially game-changing treatment for people with, or at risk of, blood clots has been found effective by an international team of researchers led by McMaster University's Jeffrey Weitz.
Weitz's team compared abelacimab with enoxaparin as a control drug in 412 patients undergoing knee replacement surgery. Results showed that just one abelacimab injection prevents blood clots for up to a month after surgery, reducing the risk by about 80% compared with enoxaparin without increasing the risk of bleeding. Their findings were published in the New England Journal of Medicine today, coinciding with Weitz's presentation of the research at the International Society on Thrombosis and Hemostasis 2021 Congress.